Revised SPC: Tecentriq (atezolizumab) 840 mg concentrate for solution for infusion
Uveitis and psoriasis have been added to SPC as rare and uncommon adverse effects, respectively.
Source:
electronic Medicines compendium
Uveitis and psoriasis have been added to SPC as rare and uncommon adverse effects, respectively.
electronic Medicines compendium